Similar research published in 2021 reported that Delta like 1 (DLL1) could promote the responsiveness of breast cancer and lung cancer to immunotherapy by mediating the normalization of tumor blood vessels and the polarization of M1-like macrophages (Zhang et al., 2021). This evidence concerns the gene DLL1 and breast carcinoma.